Side-by-side · Research reference
SurvodutidevsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED25/54 cited
BFDA-ApprovedFlagship14/45 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Survodutide
Tirzepatide
Primary target
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
—
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Survodutide
Tirzepatide
Frequency
Once weekly
—
Evidence basis
Phase 2 RCT (obesity) · Phase 3 ongoing
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
—
Once weekly, any time of day
03Metabolic / Fat Loss Evidence
Parameter
Survodutide
Tirzepatide
Primary fat target
Total body weight, visceral adipose tissue
—
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
—
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
—
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
—
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
—
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class
—
04Side Effects & Safety
Parameter
Survodutide
Tirzepatide
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022
Safety profile
Network meta-analysis: comparable safety to other GRAs
—
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
—
Injection site reactions
Expected with subcutaneous administration
—
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Pregnancy / OB
—
Contraindicated
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Survodutide
Tirzepatide
1. Reconstitution
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
Pen-supplied. Research vial: 27–31G insulin syringe.